Detalles de la búsqueda
1.
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs
; 40(3): 586-595, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35113285
2.
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Breast Cancer Res
; 22(1): 48, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414394
3.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int J Cancer
; 143(1): 151-159, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435981
4.
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
J Neurooncol
; 138(3): 489-498, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564747
5.
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Int J Cancer
; 139(9): 2095-105, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27342948
6.
B7-H3-Targeting Chimeric Antigen Receptors Epstein Barr Virus Specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3 Positive Solid Tumors.
Cancer Res Commun
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38717140
7.
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody.
Nat Med
; 11(11): 1250-5, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16258537
8.
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 160: 112-133, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34840026
9.
Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Angiogenesis
; 14(3): 245-53, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21452059
10.
Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space.
Cell Rep
; 34(3): 108657, 2021 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33472071
11.
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Sci Transl Med
; 12(555)2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32759276
12.
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.
Haematologica
; 94(10): 1456-9, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19794091
13.
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Clin Cancer Res
; 14(6): 1888-96, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18347192
14.
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.
Mol Cancer Ther
; 7(11): 3598-608, 2008 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-18974394
15.
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Theranostics
; 9(26): 8221-8238, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31754392
16.
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
MAbs
; 11(4): 666-680, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31046547
17.
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Bioconjug Chem
; 19(4): 849-59, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18370417
18.
Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015.
Mol Cancer Ther
; 17(6): 1259-1270, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545332
19.
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 4(4): e175245, 2018 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29423521
20.
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Mol Cancer Ther
; 5(11): 2613-23, 2006 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17088436